[Advanced ovarian cancer: state of the art and future perspectives].
Campisi
C
C
CNR-Istituto tecnologie biomediche, Roma.
Zappalà
A
A
Terenzi
S
S
Ravaioli
M
M
D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D004264:DNA Topoisomerases, Type I / Q000378:metabolism; D004250:DNA Topoisomerases, Type II / Q000378:metabolism; D003663:Decision Trees; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000201:enzymology / Q000601:surgery; D011379:Prognosis; D012086:Reoperation; D016879:Salvage Therapy
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004264:DNA Topoisomerases, Type I; D004250:DNA Topoisomerases, Type II